{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:40:46Z","timestamp":1792644046330,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119387","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:45:31Z","timestamp":1790783131000},"page":"119387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SMP-656: A self-catalyzed ring-opening hydrolysis linker-based ADC with enhanced stability and antitumor efficacy"],"prefix":"10.1016","volume":"320","author":[{"given":"Chaoyang","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119387_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejmech.2026.119387_bib2","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119387_bib3","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119387_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2026.119387_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119387_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119387_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119387_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119387_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1039\/D3MD00674C","article-title":"The medicinal chemistry evolution of antibody-drug conjugates","volume":"15","author":"Hobson","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/10717544.2022.2039807","article-title":"Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index","volume":"29","author":"Wang","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.119387_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acs.bioconjchem.5c00580","article-title":"Systematic evaluation of maleimide spacer impact on drug-linker deconjugation in antibody-drug conjugates Ex vivo and in vivo","volume":"37","author":"Hern\u00e1ndez Rojas","year":"2026","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/bc7004329","article-title":"Contribution of linker stability to the activities of anticancer immunoconjugates","volume":"19","author":"Alley","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib13","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1021\/bc200148v","article-title":"Tunable degradation of maleimide-thiol adducts in reducing environments","volume":"22","author":"Baldwin","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jconrel.2015.09.032","article-title":"Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides","volume":"220","author":"Christie","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119387_bib16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119387_bib17","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/bc500357n","article-title":"Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy","volume":"25","author":"Tumey","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib18","doi-asserted-by":"crossref","first-page":"10585","DOI":"10.1002\/anie.201405702","article-title":"Cysteine-selective reactions for antibody conjugation","volume":"53","author":"Cal","year":"2014","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2026.119387_bib19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/bc500148x","article-title":"Bridging disulfides for stable and defined antibody drug conjugates","volume":"25","author":"Badescu","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib20","doi-asserted-by":"crossref","first-page":"11170","DOI":"10.1021\/acs.joc.8b02686","article-title":"(Z)-Oxopropene-1,3-diyl, a linker for the conjugation of the thiol group of cysteine with amino-derivatized drugs","volume":"84","author":"Petit","year":"2019","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/10717544.2022.2039807","article-title":"Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index","volume":"29","author":"Wang","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.119387_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.119054","article-title":"An intrinsically hydrophilic linker enables a stable, high-DAR exatecan-based HER2 ADC with potent antitumor activity","volume":"316","author":"Heng","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119387_bib23","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119387_bib24","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119387_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119387_bib26","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.119387_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216024","article-title":"An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs","volume":"554","author":"Gandullo-S\u00e1nchez","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119387_bib28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/pharmaceutics16060752","article-title":"Surface-available HER2 levels alone are not indicative of cell response to HER2-Targeted antibody-drug conjugate therapies","volume":"16","author":"Major","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119387_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/cas.70319","article-title":"Therapeutic strategies to overcome payload resistance of trastuzumab deruxtecan in HER2-Positive cancers","volume":"117","author":"Murase","year":"2026","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119387_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","article-title":"Eribulin -- a review of preclinical and clinical studies","volume":"81","author":"Swami","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.119387_bib31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/molecules31071180","article-title":"Antibody-drug conjugates (ADCs): a review of structural design, technological evolution, and future perspectives","volume":"31","author":"Wu","year":"2026","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119387_bib32","first-page":"21","article-title":"Eribulin mesylate in the treatment of metastatic breast cancer","volume":"6","author":"Jain","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.ejmech.2026.119387_bib33","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119387_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119387_bib35","first-page":"221","article-title":"Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity","volume":"7","author":"Wang","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.ejmech.2026.119387_bib36","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1158\/1538-7445.AM2024-5087","article-title":"Abstract 5087: ILB-3101, a novel B7H3-targeting ADC with eribulin as payload, demonstrates strong tumor killing activities and favorable PK\/TOX profile in preclinical evaluation","volume":"84","author":"Shang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119387_bib37","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/cas.14898","article-title":"Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models","volume":"112","author":"Furuuchi","year":"2021","journal-title":"Cancer Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:20:36Z","timestamp":1792642836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"alternative-id":["S0223523426008329"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119387","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SMP-656: A self-catalyzed ring-opening hydrolysis linker-based ADC with enhanced stability and antitumor efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119387"}}